china semaglutide Novo Nordisk's Wegovy Weight-Loss Drug Gets Approval in China's GLP-1 landscape | BioWorld

14 Recommendations The results above have prompted the ADA and EASD to recommend GLP-1RAs as preferred second- or third-line injectable agents following metformin in people with: 1 established atherosclerotic cardiovascular disease a need to minimise weight gain or promote weight loss a need to minimise hypoglycaemia mild-to-moderate chronic kidney disease

CJC-1295 The green peptide was invented by a pharmaceutical company called ConjuChem Biotechnologies, hence the CJC code number

Al-Kuraishy HM, Al-Gareeb AI, Alexiou A et al (2022a) 5-HT/CGRP pathway and Sumatriptan role in Covid-19

The condition is benign and requires no treatment beyond regular monitoring